News

BioM's articles and press releases about the Bavarian biotechnology sector


Swiss Biotech Day 2025: Get your discounted ticket now!

The Swiss Bi­otech Day will again take place from 05 to 06 May 2025 in Basel (Switzer­land). The SBD has be­come one of the key events in…

m4 Award winner Tubulis starts clinical trial with ADC TUB-030 for the treatment of solid tumours

The Martin­sried-based bi­otech com­pany Tubulis has dosed the first pa­tient in its Phase I/IIa study in­vest­ig­at­ing the an­ti­body drug…

BIO-Europe Spring 2025: Early bird rate expires on 31 January - Get the 15% BioM discount now!

This March, BIO-Europe Spring re­turns for a dy­nam­ic in-per­son ex­per­i­ence, and BioM is ex­cited to in­vite you to join us! From 17 –…

RNhale receives EUR 2.5 million funding from EIC Transition Programm

The Mu­nich-based bi­otech start-up RNhale has re­ceived fund­ing as part of the European In­nov­a­tion Coun­cil (EIC) Trans­ition…

Honoring Excellence: MPG president Patrick Cramer Delivers the Inaugural Ernst-Ludwig Winnacker Lecture, Highlighting AI and Genetics in the Biomedicine Revolution

On be­half of the 41. an­nu­al Ring­berg sym­posi­um at lake Tegernsee, or­gan­ized by BioM and the Gene Center Mu­nich and co-sponsored by…

Formycon receives EU approval for aflibercept biosimilar for the treatment of severe retinal diseases

The European Com­mis­sion has ap­proved the bi­osim­il­ar afliber­cept (FYB203) from For­my­con AG, Martin­sried-Planegg, Ger­many, under…

InflaRx receives EU approval for vilobelimab for the treatment of COVID-19-related ARDS

The European Com­mis­sion has au­thor­ised GOHIBIC® (vilo­belimab) from In­flaRx in Planegg, Ger­many, for the treat­ment of adult pa­tients…

Tender Extended for the Paul Martini Prize 2025

The Paul Martini Found­a­tion an­nounces the an­nu­al Paul Martini Prize for the year 2025 and calls for in­ter­na­tion­al entries. The…

Deadline extended! BIO-Europe Spring 2025: Secure Your Spot at the Bavarian Booth!

This March, BIO-Europe Spring re­turns for a dy­nam­ic in-per­son ex­per­i­ence, and BioM is ex­cited to in­vite you to join us! From 17 –…

CatalYm publishes in Nature: Visugromab demonstrates clinical success in overcoming checkpoint inhibitor resistance

Bi­otech com­pany CatalYm from Planegg near Mu­nich pub­lished data of the first-in­hu­man Phase 1/2a study of its lead drug can­did­ate…

Newsletter

Subscribe

Archive


27.03.2025

Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie (StMWi)

Got­thardt: "Die sichere Ver­sor­gung mit Arzneimit­teln und Med­iz­in­produk­ten hat höch­ste Pri­or­ität"

26.03.2025

Friedrich-Alexander-Universität Erlangen-Nürnberg

In­nov­a­tion in der Orthopädie


Publish press release

 To the login


Gabriele Klingner
Gabriele Klingner

Communications & Marketing Lead


Christiane Proll
Christiane Proll

PR & Social Media Manager